Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma

被引：0
|
作者：
Lee, Jae Woo
Son, Jun Hyuk
Lee, Ban Seok
Lee, Sang Hyub
Jang, Dong Kee
Chung, Kwang Hyun
Ryu, Ji Kon
Kim, Yong-Tae
机构：
[1] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med, Seoul 151, South Korea
[2] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Liver Res Inst, Seoul 151, South Korea
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-8-51
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [31] Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy
    Katz, A
    Hanlon, A
    Lanciano, R
    Hoffman, J
    Coia, L
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (02): : 393 - 396
  • [32] The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.
    Mosgaard, Camilla Stedstrup
    Gramkow, Mathias Holsey
    Dehlendorff, Christian
    Nielsen, Dorte
    Pfeiffer, Per
    Qvortrup, Camilla
    Yilmaz, Mette K. N.
    Larsen, Ole
    Bojesen, Stig Egil
    Schou, Jakob Vasehus
    Boisen, Mogens Karsboel
    Johansen, Julia S.
    Jensen, Benny Vittrup
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy
    Faruk Tas
    Senem Karabulut
    Rumeysa Ciftci
    Fatma Sen
    Burak Sakar
    Rian Disci
    Derya Duranyildiz
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1163 - 1171
  • [34] Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy
    Tas, Faruk
    Karabulut, Senem
    Ciftci, Rumeysa
    Sen, Fatma
    Sakar, Burak
    Disci, Rian
    Duranyildiz, Derya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1163 - 1171
  • [35] CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer
    Ishii, H
    Okada, S
    Sato, T
    Wakasugi, H
    Saisho, H
    Furuse, J
    Ishikawa, O
    Matsuno, S
    Yokoyama, S
    HEPATO-GASTROENTEROLOGY, 1997, 44 (13) : 279 - 283
  • [36] Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy
    Bauer, Todd M.
    El-Rayes, Bassel F.
    Li, Xiaobai
    Hammad, Nazik
    Philip, Philip A.
    Shields, Anthony F.
    Zalupski, Mark M.
    Bekaii-Saab, Tanios
    CANCER, 2013, 119 (02) : 285 - 292
  • [37] Prognostic value of CA 19-9 serum course in pancreatic cancer
    Safi, F
    Schlosser, W
    Falkenreck, S
    Beger, HG
    HEPATO-GASTROENTEROLOGY, 1998, 45 (19) : 253 - 259
  • [38] Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma
    Rudnicki, J.
    Agrawal, A. K.
    Grzebieniak, Z.
    Zukrowski, P.
    Zysko, D.
    Jelen, M.
    Kielan, W.
    Sebastian, M.
    Slonina, J.
    Marek, G.
    Duda-Barcik, L.
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2010, 48 (02) : 249 - 261
  • [39] Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
    Joshua G. Barton
    John P. Bois
    Michael G. Sarr
    Christina M. Wood
    Rui Qin
    Kristine M. Thomsen
    Michael L. Kendrick
    Michael B. Farnell
    Journal of Gastrointestinal Surgery, 2009, 13 : 2050 - 2058
  • [40] Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma
    Barton, Joshua G.
    Bois, John P.
    Wood, Christina M.
    Qin, Rui
    Kendrick, Michael L.
    Farnell, Michael B.
    GASTROENTEROLOGY, 2008, 134 (04) : A871 - A871
12345